Cancer clinical trials in the region Occitanie
390 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Brain tumors / Central nervous system tumors
#NCT06556563
#2024-513550-30-00
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
None
Required previous treatments
Surgery
Chemotherapy
Radiotherapy
Radiochemotherapy
Excluded previous treatments
Systemic Treatment-Naive
Immunotherapy
5 recruiting sites
NovoCure GmbH
Phase 3
Brain tumors / Central nervous system tumors
#NCT05904119
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
1
Required previous treatments
Surgery
Radiochemotherapy
Excluded genetic anomalies
IDH1/2
Excluded previous treatments
Systemic Treatment-Naive
10 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3
Brain tumors / Central nervous system tumors
#NCT05476939
#2014-001929-32
Phase inclusion DIPG
Required histologic types
Gliomas
Required histologic sub types
Diffuse midline glioma grade IV
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Chemotherapy
Radiotherapy
32 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Brain tumors / Central nervous system tumors
#NCT05476939
#2014-001929-32
Phase inclusion - gliomes diffus de la ligne médiane non-DIPG
Required histologic types
Gliomas
Required histologic sub types
Diffuse midline glioma grade IV
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Chemotherapy
Radiotherapy
33 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Lymphoma
#NCT06006117
#2022-501810-77-00
Required histologic types
B cell lymphoma
Required histologic sub types
Marginal zone lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Chemotherapy
Targeted therapy
Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
Bispecific T-cell engager antibodies
Allogeneic stem cell transplant
23 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 3
Lung cancer
#NCT07431827
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Localized
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Immunotherapy
Chemotherapy
1 recruiting site
Merck Sharp & Dohme LLC
Phase 3
Sarcoma and GIST
#NCT07218926
#2025-522229-37-00
Required histologic types
GIST
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KIT
PDGFRA
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
GlaxoSmithKline
Phase 3
Lung cancer
#NCT07185997
#2025-522151-26-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
Bispecific T-cell engager antibodies
7 recruiting sites
ArriVent BioPharma, Inc
Phase 3
Endometrial cancer
#NCT07044336
#2024-518777-34-00
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
AstraZeneca
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT04256317
Phase 3 monothérapie
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Secondary MDS
Chronic myelomonocytic leukemia (CMML)
Other MDS
Required previous treatments
Systemic Treatment-Naive
Required IPSS-R prognostic scores
High
Very high
Required IPSS-M prognostic scores
High
Very high
Required molecular CPSS scores
Intermediate-2
High
Excluded previous treatments
Chemotherapy
3 recruiting sites
Taiho Oncology